Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.40 |
| ▸ | EDNRA | P25101 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.39 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3101392 | 0.84 | HDAC6 (0.52) | ALDH1A1NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL3107571 | 0.84 | NPC1 (0.44) | ALDH1A1NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL1597664 | 0.82 | RAB9A (0.50) | ALDH1A1NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL28630958 | 0.77 | NR4A2 (0.50) | ALDH1A1KDM4ESMN1; SMN2HSD17B10MAPK1 | |
| SCHEMBL38656298 | 0.77 | MKNK1 (0.49) | ALDH1A1NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL3091048 | 0.76 | SLC6A4 (0.51) | ALDH1A1NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL3102333 | 0.76 | ALDH1A1 (0.62) | ALDH1A1NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL3914366 | 0.76 | NPC1 (0.70) | ALDH1A1NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL2665747 | 0.76 | ALDH1A1 (0.61) | ALDH1A1NPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL18512081 | 0.73 | PDE10A (0.46) | ALDH1A1KDM4EHSD17B10MAPK1CYP1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1948146-B1 | NOVEL MULTI-CYCLIC COMPOUNDS AND THEIR USE | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2012-11-07 | — | — | EP | disclosed |
| EP-1948146-B1 | NOVEL MULTI-CYCLIC COMPOUNDS AND THEIR USE | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2012-11-07 | — | — | EP | disclosed |
| CN-101267811-B | Novel multi-cyclic compounds and their use | REVOTAR BIOPHARMACEUTICALS AG | 2012-07-25 | — | — | CN | disclosed |
| US-20090030015-A1 | NOVEL MULTI-CYCLIC COMPOUNDS | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2009-01-29 | — | — | US | disclosed |
| US-20090030015-A1 | NOVEL MULTI-CYCLIC COMPOUNDS | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2009-01-29 | — | — | US | disclosed |
| US-20090030015-A1 | NOVEL MULTI-CYCLIC COMPOUNDS | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2009-01-29 | — | — | US | disclosed |
| CN-101267811-A | Novel multi-cyclic compounds and their use | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2008-09-17 | — | — | CN | disclosed |
| EP-1948146-A2 | NOVEL MULTI-CYCLIC COMPOUNDS AND THEIR USE | Revotar Biopharmaceuticals AG (DE) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007039111-A2 | NOVEL MULTI-CYCLIC COMPOUNDS AND THEIR USE | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039111-A2 | NOVEL MULTI-CYCLIC COMPOUNDS AND THEIR USE | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030015-A1 | NOVEL MULTI-CYCLIC COMPOUNDS | SELP, SELE, SELL | ALDH1A1 608/4885NPC1 1102/4885RAB9A 2400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.